Morris Brian, Hughes Elisha, Rosenthal Eric, Gutin Alexander, Bowles Karla R
Myriad Genetics, Inc, 320 Wakara Way, Salt Lake City, UT, 84108, USA.
Myriad Genetic Laboratories, Inc, 320 Wakara Way, Salt Lake City, UT, 84108, USA.
BMC Genet. 2016 Jul 1;17(1):99. doi: 10.1186/s12863-016-0407-0.
Lynch syndrome is a hereditary cancer syndrome associated with high risks of colorectal and endometrial cancer that is caused by pathogenic variants in the mismatch repair genes (MLH1, MSH2, MSH6, PMS2, EPCAM). Accurate classification of variants identified in these genes as pathogenic or benign enables informed medical management decisions. Previously, we developed a clinical History Weighting Algorithm (HWA) for the classification of variants of uncertain significance (VUSs) in BRCA1 and BRCA2. The BRCA1/2 HWA is based on the premise that pathogenic variants in these genes will be identified more often in individuals with strong personal and/or family histories of breast and/or ovarian cancer, while the identification of benign variants should be independent of cancer history. Here we report the development of a similar HWA to allow for classification of VUSs in genes associated with Lynch syndrome using data collected through both syndrome-specific and pan-cancer panel testing.
Upon completion of algorithm development, the HWA was tested using simulated variants constructed from 79,214 probands, as well as 379 true variants. Positive (PPV) and negative predictive values (NPV) were calculated on a per gene basis.
25,500 pathogenic and 50,500 benign simulated variants were analyzed using the HWA and the PPVs and NPVs for each gene were greater than 0.997 and 0.999, respectively. The HWA was also evaluated using 100 trials for each of the 379 true variants. PPVs of >0.998 and NPVs of >0.999 were obtained for all genes.
We have developed and implemented a HWA to aid in the classification of VUSs in genes associated with Lynch syndrome. The work presented here demonstrates that this HWA is able to classify MLH1, MSH2, and MSH6 VUSs as either benign or pathogenic with high accuracy.
林奇综合征是一种遗传性癌症综合征,与结直肠癌和子宫内膜癌的高风险相关,由错配修复基因(MLH1、MSH2、MSH6、PMS2、EPCAM)中的致病变异引起。将这些基因中鉴定出的变异准确分类为致病性或良性,有助于做出明智的医疗管理决策。此前,我们开发了一种临床病史加权算法(HWA),用于对BRCA1和BRCA2中意义未明的变异(VUS)进行分类。BRCA1/2 HWA基于这样一个前提,即这些基因中的致病变异在有强烈个人和/或家族乳腺癌和/或卵巢癌病史的个体中更常被发现,而良性变异的鉴定应与癌症病史无关。在此,我们报告开发了一种类似的HWA,以便使用通过综合征特异性和泛癌基因检测收集的数据,对与林奇综合征相关基因中的VUS进行分类。
算法开发完成后,使用从79214名先证者构建的模拟变异以及379个真实变异对HWA进行测试。按每个基因计算阳性预测值(PPV)和阴性预测值(NPV)。
使用HWA分析了25500个致病性和50500个良性模拟变异,每个基因的PPV和NPV分别大于0.997和0.999。还对379个真实变异中的每一个进行了100次试验,以评估HWA。所有基因的PPV均大于0.998,NPV均大于0.999。
我们开发并实施了一种HWA,以帮助对与林奇综合征相关基因中的VUS进行分类。本文介绍的工作表明,这种HWA能够将MLH1、MSH2和MSH6的VUS准确分类为良性或致病性。